Autoimmune Lymphoproliferative Syndrome Type 5 (ALPS-5)

Autoimmune Lymphoproliferative Syndrome type 5 (ALPS-5) is a rare immune system disease. It happens when a gene called CTLA4 does not make enough working protein (this is called “haploinsufficiency”). CTLA-4 is a brake on immune cells. When the brake is weak, immune cells can grow too much and attack the body’s own cells. People then get big lymph nodes and spleen, low blood counts from autoimmunity (like autoimmune anemia or low platelets), repeated infections, gut problems, and a higher risk of some lymphomas. Doctors used to group many ALPS cases by defects in the FAS death-signal pathway, but ALPS-5 specifically points to CTLA4 problems, often called CHAI (CTLA-4 haploinsufficiency with autoimmune infiltration). rarediseases.info.nih.gov+2monarchinitiative.org+2

Autoimmune lymphoproliferative syndrome type 5 is the name some sources use for a disorder caused by having only one working copy of the CTLA4 gene—often called CTLA-4 haploinsufficiency or CHAI disease. CTLA-4 is a “brake” on T-cells. When that brake is weak, the immune system does not turn itself down properly. As a result, immune cells can grow too much (lymphoproliferation), attack the body’s own tissues (autoimmunity), and at the same time leave people prone to infections because parts of the immune system become exhausted or unbalanced. The condition is usually autosomal dominant with variable penetrance (some carriers are much sicker than others). Typical problems include big lymph nodes and spleen, autoimmune destruction of blood cells (anemia, low platelets, or low neutrophils), bowel inflammation (enteropathy), lung inflammation (often GLILD), and low antibodies (hypogammaglobulinemia). SpringerOpen+3NCBI+3Orpha+3

CTLA-4 sits on T cells and acts like a strong brake. It binds to the same docking sites (CD80/CD86) that turn T cells “on,” but CTLA-4 turns them “off” and also pulls those docking sites away from the cell surface. If one CTLA4 gene copy does not work, the brake is weak. T cells become overactive, do not calm down after infections, and can invade organs such as the gut and lungs. This overactivity also disturbs B cells, causing high antibodies against self (autoantibodies) and sometimes low protective antibodies (hypogammaglobulinemia), so infections happen more easily. The end result is lymph node and spleen enlargement, autoimmune cytopenias, and tissue inflammation. PMC

A note on names and classification: newer expert frameworks group CTLA-4 haploinsufficiency with the autoimmune lymphoproliferative immunodeficiencies (ALPIDs)—closely related to classic ALPS but genetically distinct. Older or ontology-style resources still list it as “ALPS type V (type 5).” You may see both in the literature. JA Connections+1

Other names

This same condition appears in databases and papers under several labels. All point to the same CTLA-4–related disease:

• CTLA-4 haploinsufficiency with autoimmune infiltration (CHAI)

• Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency

• Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation

• ALPS type V / ALPS type 5
  These synonyms are captured in ClinVar, MedGen, Monarch Initiative, and ClinGen condition records. search.clinicalgenome.org+3NCBI+3NCBI+3

Types

Doctors have described several ALPS and ALPS-related categories:

• Classic ALPS subtypes center on the Fas/FasL apoptosis pathway:

  • ALPS-FAS (germline FAS), ALPS-sFAS (somatic FAS), ALPS-FASLG (FAS ligand), ALPS-CASP10 (caspase-10), and ALPS-U (no gene found). NCBI

• ALPS-like/RAS-related disorders were once labeled “ALPS type IV” (e.g., NRAS/KRAS) but are now often separated as RALD rather than strict ALPS. ASHP Publications+2ASHP Publications+2

• ALPS type V (type 5) in ontology databases refers to CTLA-4 haploinsufficiency—functionally an immune-checkpoint deficiency now grouped within ALPIDs. NCBI+1

Take-home: Whether a report calls CTLA-4 disease “ALPS-V” or “CHAI/ALPID,” the clinical idea is the same: insufficient CTLA-4 braking → lymphoproliferation + autoimmunity + frequent antibody deficiency. ScienceDirect

Causes

Below are 20 drivers and contributors that explain why ALPS type 5 happens and why it looks the way it does. The core cause is genetic; the rest describe biological consequences and modifiers that shape the symptoms.

1. Heterozygous pathogenic variants in CTLA4 (haploinsufficiency). One faulty CTLA4 copy yields too little CTLA-4 protein and weak inhibitory signaling on T-cells. NCBI+1

2. Autosomal-dominant inheritance. Affected parents can pass the variant to children with a 50% chance; penetrance is variable. Immune Deficiency Foundation

3. De novo (new) CTLA4 variants. Some individuals are the first in their family with the change. (Described across CTLA-4 series.) Immune Deficiency Foundation

4. Variable penetrance. Some carriers are almost well; others have severe disease, reflecting modifiers and environment. Immune Deficiency Foundation

5. Regulatory T-cell (Treg) dysfunction. CTLA-4 is central to Treg suppression; reduced function permits autoimmunity and tissue infiltration. ScienceDirect

6. Excess T follicular helper (Tfh) activity. CTLA-4 insufficiency shifts helper T-cell balance, driving B-cell activation and autoantibodies. PMC

7. Faulty “checkpoint” control after infections. Without adequate CTLA-4 braking, activated T-cells persist and expand. ScienceDirect

8. B-cell maturation defects. Many patients have low switched-memory B cells and hypogammaglobulinemia, predisposing to infections. SpringerOpen

9. Autoantibody formation. Loss of tolerance promotes antibodies that attack blood cells or organs (e.g., AIHA, ITP, neutropenia). Orpha

10. Lymphocytic infiltration of non-lymphoid organs. Overactive T/B cells infiltrate gut, lung, brain, kidney, and others, causing inflammation. Orpha

11. Enteropathy (gut immune dysregulation). CTLA-4 pathway weakness promotes chronic intestinal inflammation. Orpha

12. Granulomatous-lymphocytic interstitial lung disease (GLILD). A frequent lung manifestation of checkpoint insufficiency. Wikipedia

13. Hypogammaglobulinemia-driven infection cycles. Recurrent infections can flare immune activation and autoimmunity. Orpha

14. Genetic/immune background modifiers. Other immune genes likely modify severity and presentation (not fully mapped). JA Connections

15. Environmental triggers. Intercurrent infections and vaccines rarely unmask disease activity in predisposed hosts (general ALPID observation). JA Connections

16. Age-related expression. Symptoms often begin in childhood or adolescence but can appear in adults as recognition improves. JA Connections

17. Overlap with CVID phenotype. CTLA-4 disease can look like common variable immunodeficiency, which delays diagnosis. SpringerOpen

18. Somatic mosaicism (rare). Mosaic CTLA4 variants can theoretically lessen or vary disease; databases note heterogeneity, though classic cases are germline. NCBI

19. Histopathology differences vs classic ALPS. CTLA-4 disease may lack large expansions of double-negative T cells and shows different lymph-node patterns. PMC

20. Historical naming/diagnostic frameworks. Whether labeled ALPS-V or CHAI, the underlying cause remains CTLA-4 checkpoint failure. NCBI

Symptoms and signs

1. Enlarged lymph nodes (lymphadenopathy). Nodes become big and persist because T-cells keep growing and do not shut down. Orpha

2. Big spleen (splenomegaly) and sometimes big liver (hepatomegaly). Persistent immune activation makes these organs enlarge. Orpha

3. Autoimmune hemolytic anemia. The immune system destroys red blood cells, causing pallor, jaundice, and fatigue. Wikipedia

4. Immune thrombocytopenia (ITP). The immune system attacks platelets, leading to easy bruising and nosebleeds. Wikipedia

5. Autoimmune neutropenia. Low neutrophils raise infection risk and may cause mouth ulcers or fevers. Wikipedia

6. Recurrent infections. Low antibodies and unbalanced immunity lead to frequent sinus, ear, chest, or other infections. Orpha

7. Chronic diarrhea and abdominal pain (enteropathy). Immune cells inflame the gut lining, causing malabsorption and weight loss. Orpha

8. Lung problems (e.g., GLILD). Breathlessness or cough from inflammatory changes in the lungs. Wikipedia

9. Polyclonal lymphocytosis and hypergammaglobulinemia or, more often here, hypogammaglobulinemia. Antibody levels can be abnormal; in CTLA-4 disease they are frequently low. SpringerOpen

10. Autoimmune thyroid, liver, or skin disease. The same loss of tolerance may involve many organs. JA Connections

11. Fatigue and low energy. Caused by anemia, inflammation, and chronic illness burden. JA Connections

12. Fever of unknown origin. Ongoing immune activation can cause intermittent fevers. JA Connections

13. Headaches or neurologic symptoms (less common). Due to inflammatory infiltration in nervous system tissues. Orpha

14. Growth or nutrition problems in children. Long-standing gut or systemic inflammation affects growth. Orpha

15. Risk of lymphoid malignancy (uncertain but monitored). Long-term immune dysregulation requires vigilance. (Risk is well-described in classic ALPS; CTLA-4 disease is monitored similarly.) NCBI

Diagnostic tests

The goal is to prove CTLA-4–related immune dysregulation, assess damage, and exclude look-alikes. Below are common tests explained in plain language.

A) Physical-exam–based

1. Full lymph-node and spleen exam. Doctors feel for enlarged nodes in the neck, armpits, and groin, and measure spleen size. Persistent, symmetric enlargement suggests immune overgrowth rather than acute infection. Orpha

2. Growth and nutrition check. Weight, height, and pubertal status help flag chronic enteropathy or inflammation. Orpha

3. Skin, mouth, and eye inspection. Petechiae or bruises suggest thrombocytopenia; mouth ulcers can hint at neutropenia; rashes suggest autoimmunity. Wikipedia

4. Respiratory exam. Crackles or decreased breath sounds can raise suspicion for GLILD or pneumonia. Wikipedia

B) “Manual bedside tests and simple procedures

5. Palpation-guided spleen measurement and percussion. A simple bedside way to follow spleen size over time. Orpha

6. Stool guaiac testing if diarrhea or weight loss. Screens for intestinal bleeding due to enteropathy; prompts endoscopy if positive. Orpha

7. Peak-flow or handheld spirometry screening. A quick clinic screen for reduced airflow before formal lung testing when cough or dyspnea is present. Wikipedia

These bedside tests do not diagnose ALPS type 5 by themselves; they flag problems that require lab and imaging confirmation.

C) Laboratory and pathology tests

8. Complete blood count (CBC) with smear. Looks for anemia, low platelets, and neutropenia typical of autoimmune cytopenias. The smear may show evidence of hemolysis. Wikipedia

9. Direct antiglobulin (Coombs) test. Confirms autoimmune hemolysis when anemia is present. Wikipedia

10. Quantitative immunoglobulins (IgG, IgA, IgM). Many patients show hypogammaglobulinemia; this supports the diagnosis and guides therapy. SpringerOpen

11. Specific antibody titers (e.g., after vaccines). Poor responses suggest functional antibody deficiency even when total Ig levels are borderline. SpringerOpen

12. Flow cytometry of lymphocyte subsets. Important patterns include reduced switched-memory B cells and reduced CTLA-4 expression on T cells; in contrast to classic ALPS, double-negative T cells may be normal or only mildly increased. SpringerOpen+1

13. ALPS biomarker panel. In classic ALPS, soluble FasL, IL-10, IL-18, and vitamin B12 are often high; in CTLA-4 disease, these may be less specific but can aid the work-up and the differential. NCBI

14. Apoptosis (Fas-mediated) assay (research/tertiary centers). More useful for classic ALPS; results help separate Fas-pathway disease from CTLA-4 disease. NCBI

15. Genetic testing for CTLA4 (sequencing ± deletion/duplication). This is the definitive test for ALPS type 5/CHAI—identifies a heterozygous pathogenic variant. NCBI

16. Lymph-node or tissue biopsy when indicated. Shows reactive lymphoid hyperplasia; in CTLA-4 disease, studies describe patterns distinct from classic ALPS (e.g., ectopic inducible MALT, less prominent DNT expansion). PMC

D) Electrodiagnostic studies

17. Usually not required. Nerve conduction studies or EMG are not part of routine ALPS/ALPID evaluation. They are considered only if a patient has unusual neuromuscular symptoms that need separate work-up. This is standard practice in immunology—electrodiagnostics evaluate nerves/muscles, not immune regulation. JA Connections

E) Imaging tests

18. Abdominal ultrasound. Safely tracks spleen and liver size and monitors lymph nodes in the abdomen over time. Medscape

19. Chest CT (and sometimes HRCT). Looks for GLILD or other interstitial lung disease when cough or breathlessness persists. Wikipedia

20. PET-CT or targeted CT/MRI when lymphoma is suspected or when tissue sites of inflammation must be mapped before biopsy. (Classic ALPS has a lymphoma risk; CT imaging helps triage.) NCBI

Non-pharmacological treatments (therapies & others)

(Each item: ~150 words with purpose & mechanism in plain English)

1. Education and shared-care plan
   Description: You and your family learn what ALPS-5 is, the common flares, infection risks, and red flags. You keep a simple written plan that lists your diagnoses, medicines, doses, and emergency contacts. Purpose: To act early when problems start and to avoid unsafe medicines or live vaccines when told to avoid them. Mechanism: Knowledge reduces delays and medical errors. It supports fast action if bleeding, high fever, severe abdominal pain, or breathing problems occur. Family and school know when to call the clinic. This organized approach is proven to improve outcomes in complex immune diseases by coordinating care and avoiding missed steps. Immune Deficiency Foundation

2. Regular infection prevention habits
   Description: Hand hygiene, safe food and water practices, dental care, and avoiding close contact with sick individuals during flares. Keep up to date with inactivated vaccines and household “cocooning” (flu, COVID-19 inactivated formulations where appropriate). Purpose: Reduce infections that can trigger immune flares or cause serious illness when antibodies are low. Mechanism: Fewer exposures mean fewer immune activations. In immunodeficiency, basics like handwashing and dental hygiene reduce bacterial load and bloodstream infection risk. Vaccination strategy is tailored by your immunologist (avoid live vaccines if antibody or T-cell functions are insufficient). Immune Deficiency Foundation

3. Nutrition therapy
   Description: Balanced calories with enough protein, iron, folate, B12, and vitamin D; extra calcium and vitamin D if on long-term steroids. For gut inflammation, choose low-residue or gentle diets during flares and re-introduce fiber slowly during calm periods. Purpose: Support blood cell production, bone health, and recovery. Mechanism: Adequate protein and micronutrients help bone marrow make blood cells and help tissues heal. Vitamin D and calcium prevent steroid-related bone loss. Adjusting fiber and fat reduces gut irritation when the intestine is inflamed. Medscape

4. Physical activity (graded, symptom-paced)
   Description: Gentle daily movement with rest breaks; build endurance slowly. Avoid contact sports if spleen is enlarged. Purpose: Maintain muscle, mood, and bone strength; lower steroid side effects. Mechanism: Activity counters fatigue and steroid-related weight gain, improves insulin sensitivity, and supports bone loading for density. Protecting an enlarged spleen lowers rupture risk. Medscape

5. Sun and skin care
   Description: Treat rashes promptly, use sunscreen, and moisturize dry or inflamed skin. Purpose: Reduce skin flares and infections through intact skin barrier. Mechanism: Preserving the skin barrier prevents bacterial entry and reduces immune triggers from ultraviolet light in photosensitive patients. Medscape

6. Bone health program
   Description: Baseline vitamin D level, calcium intake check, weight-bearing exercise, and DEXA scans if on chronic steroids. Purpose: Prevent osteoporosis and fractures. Mechanism: Steroids increase bone loss; proactive monitoring and supplementation protect bones. Medscape

7. Oral and dental care
   Description: Regular dental cleanings, daily brushing and flossing, prompt care for mouth ulcers. Purpose: Reduce fevers and bacteremia originating from gums, which can be dangerous in immunodeficiency. Mechanism: Lowering oral bacterial load reduces blood seeding and inflammatory triggers. Immune Deficiency Foundation

8. All-team care coordination
   Description: A lead immunologist coordinates with hematology, gastroenterology, pulmonology, and (when needed) oncology and transplant. Purpose: One integrated plan avoids conflicting drugs and duplicated tests. Mechanism: Multidisciplinary conferences align goals and timing for imaging, infusions, and procedures, which improves outcomes in complex immune dysregulation disorders. JA Connections

9. Psychological support and stress management
   Description: Access to counseling; simple breathing, mindfulness, or CBT tools; family support groups. Purpose: Reduce anxiety, depression, and treatment fatigue. Mechanism: Lower stress hormones lessen symptom perception and may help immune balance; better adherence and coping improve overall health. Immune Deficiency Foundation

10. School and work accommodations
    Description: Flexible schedules during flares, rest breaks, and infection-control seating. Purpose: Maintain participation while reducing risk. Mechanism: Reasonable accommodations prevent setbacks and keep social and cognitive development on track. Immune Deficiency Foundation

11. Bleeding-risk safety plan
    Description: Avoid contact sports or NSAIDs if platelets are low; use protective gear; know when to seek urgent help. Purpose: Prevent serious bleeding in autoimmune thrombocytopenia. Mechanism: Minimizing trauma and platelet-affecting drugs reduces bleeding events while counts are recovering. Medscape

12. Fertility and pregnancy counseling
    Description: Pre-pregnancy visit to review safe medicines and inheritance (autosomal dominant). Purpose: Plan safe therapy and understand genetic risks. Mechanism: Counseling allows early adjustments and supports maternal and fetal health. NCBI

13. Travel planning
    Description: Carry a medication list, emergency letter, and plan vaccine timing; consider masks in crowded settings. Purpose: Reduce infection exposure and ensure quick care if problems arise away from home. Mechanism: Preparation shortens time to treatment and lowers exposure risk. Immune Deficiency Foundation

14. Vaccination strategy (specialist-guided)
    Description: Use inactivated vaccines as recommended; household members keep vaccines up-to-date. Avoid live vaccines if advised due to immunodeficiency. Purpose: Prevent severe infections that trigger flares. Mechanism: Indirect and direct protection reduce illness and hospitalizations. Immune Deficiency Foundation

15. Sleep and circadian health
    Description: Regular sleep schedule and sleep-apnea screening if there is massive lymphoid tissue. Purpose: Support immune balance and daytime energy. Mechanism: Good sleep supports immune regulation and steroid side effect control. Medscape

16. Sunrise-light and mood routine
    Description: Morning outdoor light, light physical activity, and brief mindfulness. Purpose: Improve fatigue and mood. Mechanism: Light anchors circadian rhythm and reduces stress signals. Immune Deficiency Foundation

17. Infection action plan
    Description: At the first fever ≥38.0 °C, call your team; have a local lab order ready; start antibiotics only if prescribed. Purpose: Catch infections early in immunodeficiency. Mechanism: Faster evaluation prevents complications and secondary immune flares. Immune Deficiency Foundation

18. Household “sick-day” rules
    Description: Separate towels/dishes, open windows, clean high-touch surfaces, and mask if someone is ill. Purpose: Cut transmission inside the home. Mechanism: Simple barriers lower viral and bacterial dose. Immune Deficiency Foundation

19. Medication safety checklist
    Description: Keep a one-page list of all drugs, allergies, and doses; update at each visit. Purpose: Avoid interactions and duplications. Mechanism: Clear records reduce errors during emergencies or admissions. JA Connections

20. Peer support networks
    Description: Patient groups for ALPS/primary immunodeficiencies. Purpose: Emotional support, shared tips, and advocacy. Mechanism: Community knowledge improves coping and adherence. Immune Deficiency Foundation

---

Drug treatments

1. Abatacept (CTLA-4-Ig)
   Class: Costimulation blocker. Use: Core targeted therapy for CTLA-4 haploinsufficiency; often improves autoimmunity, lymphadenopathy, enteropathy, and lung disease. Typical dosing: 10 mg/kg IV at weeks 0, 2, 4 then every 4 weeks; or SC weekly (adult fixed doses exist). Timing: Maintenance; months to assess full effect. Purpose: Replace the missing CTLA-4 “brake.” Mechanism: Binds CD80/CD86 to block CD28 costimulation, calming T-cell activation and tissue infiltration. Side effects: Headache, infections, infusion reactions; screen for TB/hepatitis as per biologics guidance. ash.confex.com+1

2. Sirolimus (rapamycin)
   Class: mTOR inhibitor. Use: Autoimmune cytopenias and lymphoproliferation; sometimes combined with abatacept. Dose: Often starts ~1–2 mg daily (target trough chosen by clinician). Timing: Weeks to months for response. Purpose/Mechanism: Dampens T-cell proliferation; can reduce double-negative T cells and shrink spleen/nodes. Side effects: Mouth ulcers, high lipids, edema, cytopenias; drug interactions via CYP3A4. PMC

3. Mycophenolate mofetil (MMF)
   Class: Antimetabolite. Use: Maintenance steroid-sparing for autoimmune cytopenias and organ inflammation. Dose: Adults often 1–1.5 g twice daily; pediatric weight-based. Mechanism: Inhibits inosine monophosphate dehydrogenase to curb lymphocyte proliferation. Side effects: GI upset, cytopenias, infection risk; teratogenic—contraception needed. Medscape

4. Rituximab
   Class: Anti-CD20 monoclonal antibody. Use: Refractory autoimmune hemolytic anemia or thrombocytopenia. Dose: 375 mg/m² weekly ×4 (common regimen). Mechanism: Depletes B cells making autoantibodies. Side effects: Infusion reactions, hypogammaglobulinemia, reactivation risks (HBV); vaccines less effective afterwards. Medscape

5. Corticosteroids (e.g., prednisone)
   Class: Glucocorticoid. Use: First-line for acute autoimmune cytopenias; taper as soon as possible. Dose: Often 1–2 mg/kg/day initially, then taper. Mechanism: Broad anti-inflammatory and lympholytic effects. Side effects: Weight gain, mood change, high sugar, hypertension, bone loss, infection risk; use bone protection. Medscape

6. IVIG (intravenous immunoglobulin)
   Class: Polyclonal IgG. Use: Treat immune thrombocytopenia flares; replace antibodies when IgG is low or infections are frequent. Dose: 1–2 g/kg for ITP; 0.4–0.6 g/kg monthly for replacement (tailored). Mechanism: Modulates Fc receptors and supplies protective antibodies. Side effects: Headache, aseptic meningitis, thrombosis risk in predisposed people; hydrate well. Medscape

7. SCIG (subcutaneous immunoglobulin)
   Class: IgG replacement. Use: Long-term infection prevention when hypogammaglobulinemia persists. Dose: Weekly or biweekly by pump; total monthly grams similar to IVIG. Mechanism/Side effects: Steady IgG levels; local site reactions common but mild. Medscape

8. Azathioprine
   Class: Purine analog immunosuppressant. Use: Steroid-sparing for autoimmune cytopenias/organ disease when MMF not suitable. Dose: Often ~1–2 mg/kg/day; check TPMT/NUDT15. Mechanism: Reduces lymphocyte proliferation. Side effects: Cytopenias, liver toxicity, infection risk; drug interactions with allopurinol. Medscape

9. Tacrolimus or Cyclosporine
   Class: Calcineurin inhibitors. Use: Refractory autoimmunity or enteropathy. Dose: Trough-guided. Mechanism: Blocks IL-2 signaling and T-cell activation. Side effects: Kidney dysfunction, hypertension, tremor, high potassium, infections; many drug interactions. Medscape

10. Hydroxychloroquine
    Class: Antimalarial immunomodulator. Use: Adjunct for milder rash or arthritis-like symptoms. Dose: ≤5 mg/kg/day (actual body weight). Mechanism: Interferes with antigen processing and toll-like receptor signaling. Side effects: Rare retinal toxicity—regular eye exams; GI upset. Medscape

11. Methotrexate (low-dose weekly)
    Class: Antimetabolite/antifolate. Use: Joint or skin inflammation not controlled by other agents. Dose: Weekly dosing with folic acid. Mechanism: Anti-inflammatory effects via adenosine pathways. Side effects: Liver toxicity, cytopenias, mouth sores; avoid in pregnancy; monitor labs. Medscape

12. Belatacept
    Class: CTLA-4-Ig (higher-affinity variant). Use: Alternative when abatacept not available; evidence mainly extrapolated. Dose: IV per transplant protocols, adapted case-by-case. Mechanism: Similar to abatacept—blocks CD28 costimulation. Side effects: Infection risk; EBV-negative patients at risk for PTLD—specialist oversight required. JA Connections

13. Eltrombopag
    Class: Thrombopoietin receptor agonist. Use: Persistent immune thrombocytopenia. Dose: Daily oral; adjust to platelet response; avoid with certain foods/minerals. Mechanism: Stimulates platelet production. Side effects: Liver enzyme elevation, thrombosis risk; eye monitoring for cataracts with long use. Medscape

14. Romiplostim
    Class: Thrombopoietin receptor agonist (peptibody). Use: Chronic ITP when other measures fail. Dose: Weekly SC; titrate to platelet target. Mechanism/Side effects: As above; monitor counts to avoid excessive rise. Medscape

15. G-CSF (filgrastim/pegfilgrastim)
    Class: Myeloid growth factor. Use: Severe neutropenia with infections. Dose: Weight-based; daily or long-acting per specialist. Mechanism: Stimulates neutrophil production. Side effects: Bone pain, spleen enlargement risk—monitor spleen size. Medscape

16. Budesonide (gut-targeted steroid)
    Class: Topical-acting glucocorticoid. Use: Enteropathy with fewer systemic effects. Dose: 9 mg/day then taper (adult typical). Mechanism: High first-pass liver metabolism limits systemic exposure. Side effects: Less than systemic steroids but still possible. Medscape

17. Vedolizumab
    Class: Anti-integrin (gut-selective). Use: Severe CTLA-4–related enteropathy not controlled by other drugs. Dose: 0, 2, 6 weeks then every 8 weeks IV. Mechanism: Blocks gut T-cell trafficking. Side effects: Infusion reactions, infections; specialist centers use case-by-case. JA Connections

18. Ustekinumab
    Class: Anti-IL-12/23. Use: Selected refractory enteropathy/skin disease. Dose: Weight-based IV load then SC maintenance. Mechanism: Reduces Th1/Th17 inflammation. Side effects: Infections; monitor. JA Connections

19. Tofacitinib (JAK inhibitor)
    Class: Targeted small-molecule. Use: Select refractory autoimmunity in expert centers. Dose: 5 mg twice daily (adult typical; adjust for risks). Mechanism: Broad cytokine signal dampening. Side effects: Herpes zoster, lipids, clot risk in some settings; careful screening. JA Connections

20. Antimicrobial prophylaxis (individualized)
    Class: Antibiotics/antivirals per risk. Use: Recurrent infections or during strong immunosuppression. Dose/Timing: Tailored. Mechanism: Prevents infections that can trigger flares. Side effects: Drug-specific; stewardship matters. Medscape

---

Dietary molecular supplements

(Evidence in ALPS-5 is limited; use only with your physician. Mechanisms and doses are general—avoid if interacting with your medicines.)

1. Vitamin D — Dose: often 800–2000 IU/day (adjust to blood level). Function/Mechanism: Supports bone health (especially with steroids) and may help immune balance. Medscape

2. Calcium — Dose: dietary total ~1000–1200 mg/day if on steroids. Function: Bone protection. Mechanism: Replaces losses and supports bone remodeling. Medscape

3. Folate — Dose: 0.4–1 mg/day (higher with methotrexate as prescribed). Function: Reduce mouth sores and cytopenia risk with antifolates. Mechanism: Replenishes folate stores. Medscape

4. Vitamin B12 — Dose: guided by labs. Function: Support red blood cell production if low. Mechanism: Cofactor for DNA synthesis. PMC

5. Iron — Dose: based on ferritin/TSAT; oral elemental iron per clinician. Function: Treat iron-deficiency anemia if present. Mechanism: Supplies hemoglobin building blocks. Medscape

6. Omega-3 fatty acids — Dose: 1–2 g/day EPA+DHA (ask about bleeding risk if platelets low). Function: Gentle anti-inflammatory support. Mechanism: Competes with arachidonic acid pathways. Medscape

7. Probiotics (selected strains) — Dose: product-specific; avoid in severe immunosuppression unless approved. Function: Gut symptom support during remission. Mechanism: Microbiome signaling may modulate gut inflammation. JA Connections

8. Zinc (short course if deficient) — Dose: typically 10–20 mg/day elemental, time-limited. Function: Immune and wound support in deficiency. Mechanism: Cofactor for immune enzymes. Medscape

9. Magnesium (if low) — Dose: per labs. Function: Muscle and nerve support; some drugs lower Mg. Mechanism: Electrolyte balance. Medscape

10. Multinutrient medical nutrition during flares — Dose: dietitian-guided shakes to sustain calories/protein. Function: Prevent weight loss in enteropathy. Mechanism: Easier absorption with lower gut work. Medscape

---

Immunity-supporting / regenerative / stem-cell–related” therapies

(Candid, safety-first: none of these are over-the-counter “boosters.” Use only under specialist care.)

1. Immunoglobulin replacement (IVIG/SCIG) — Dose: individualized monthly/weekly. Function: Replaces missing antibodies; prevents infections. Mechanism: Passive immunity. Medscape

2. G-CSF (filgrastim/pegfilgrastim) — Dose: weight-based. Function: Raises neutrophils during severe neutropenia. Mechanism: Stimulates marrow progenitors. Medscape

3. Thrombopoietin receptor agonists (eltrombopag/romiplostim) — Dose: titrated. Function: Increase platelets in chronic ITP. Mechanism: Drives megakaryocyte growth. Medscape

4. Hematopoietic Stem Cell Transplant (HSCT) — Procedure, not a pill. Function: Potential cure in severe, refractory cases. Mechanism: Replaces the immune system with donor stem cells carrying normal CTLA4 function. Dose: Conditioning and donor selection are individualized. JA Connections

5. Abatacept maintenance — Dose: IV/SC per protocol. Function: Functional “replacement” of CTLA-4 signaling. Mechanism: Restores immune braking to prevent organ infiltration. ash.confex.com

6. Belatacept (selected cases) — Dose: IV; specialist use. Function: Alternative CTLA-4-Ig when abatacept unsuitable. Mechanism: Higher-affinity CD80/CD86 binding for costimulation block. JA Connections

---

Surgeries / procedures (what they are and why)

1. Hematopoietic stem cell transplantation (HSCT)
   What: Transplant of donor stem cells after conditioning.
   Why: Considered for life-threatening, treatment-refractory disease to reset the immune system. JA Connections

2. Splenectomy (now uncommon)
   What: Surgical removal of the spleen.
   Why: Historically used for severe hypersplenism with destructive cytopenias; today avoided if possible due to lifelong sepsis risk. Medscape

3. Lymph node or organ biopsy
   What: Tissue sampling.
   Why: Rule out lymphoma or confirm inflammatory infiltration when the diagnosis is unclear. PMC

4. Central venous access placement
   What: Port or line for repeated IV treatments.
   Why: Needed for frequent infusions (IVIG, biologics) in some patients. Medscape

5. Endoscopy/colonoscopy with biopsies
   What: Camera tests of the gut.
   Why: Diagnose and grade enteropathy; guide therapy choices. JA Connections

---

Preventions (practical, everyday)

1. Wash hands often and use alcohol gel after public contact. Immune Deficiency Foundation

2. Keep inactivated vaccines current (patient and household). Immune Deficiency Foundation

3. Avoid live vaccines if your specialist advises (depends on immune status). Immune Deficiency Foundation

4. Treat dental issues early; maintain daily flossing/brushing. Immune Deficiency Foundation

5. Use masks in crowded indoor spaces during high virus seasons. Immune Deficiency Foundation

6. Build a steroid-safety plan (bone protection, BP and glucose checks). Medscape

7. Avoid contact sports with an enlarged spleen. Medscape

8. Keep a medication/allergy list and emergency letter. JA Connections

9. Plan quick evaluation for fevers ≥38 °C. Immune Deficiency Foundation

10. Coordinate all care through one specialist team. JA Connections

---

When to see doctors urgently

• Fever ≥38 °C, shaking chills, shortness of breath, chest pain, bad cough, or severe sore throat.

• Bleeding (nose/mouth that won’t stop, blood in stool/urine), or large new bruises.

• Severe belly pain, swelling, or fast growth of a lymph node.

• Severe fatigue, pallor, or fainting (possible anemia).

• Sudden neurologic changes (severe headache, vision or speech problems).
  These can signal infection, dangerous cytopenias, or organ inflammation and need fast assessment. Immune Deficiency Foundation+1

---

Foods to favor and to limit

Eat more of:

• Lean proteins (fish, eggs, poultry, legumes) to support blood cell production.

• Iron-rich foods (lean red meat, beans, spinach) when iron is low (per labs).

• Folate/B12 sources (greens, beans; dairy/eggs/fortified foods) if low.

• Calcium and vitamin-D foods (dairy, fortified alternatives, small-bone fish) especially on steroids.

• Cooked fruits/vegetables during gut flares, then slowly add fiber back. Medscape

Limit or avoid:

• Alcohol (raises bleeding risk, interacts with drugs).

• Raw or undercooked meat/eggs/fish and unpasteurized dairy (infection risk).

• High-sugar ultra-processed foods (worsen steroid weight gain and glucose).

• Grapefruit with certain medicines (drug interactions).

• NSAIDs if platelets are low or there is gut bleeding risk (ask your team). Medscape

---

Frequently asked questions

1. Is ALPS-5 the same as classic ALPS?
   No. Classic ALPS usually involves the FAS pathway. ALPS-5 is due to CTLA-4 haploinsufficiency. They overlap but are genetically distinct. PMC+1

2. What gene is involved?
   CTLA4. One faulty copy reduces CTLA-4 protein, weakening T-cell brakes. monarchinitiative.org

3. How is it inherited?
   Often autosomal dominant—a parent may have mild or different symptoms. NCBI

4. Why do I have low blood counts?
   Autoimmune attack on blood cells and spleen enlargement can destroy cells. PMC

5. What tests help with diagnosis?
   Genetic testing for CTLA4, immune panels (IgG, vaccine responses), double-negative T cells, and sometimes biopsies. PMC

6. What is the main targeted treatment?
   Abatacept (CTLA-4-Ig) is commonly used to restore the missing brake. ash.confex.com

7. Will I need lifelong treatment?
   Many need long-term control with biologics or steroid-sparing drugs; plans are individualized. JA Connections

8. Can immunoglobulin replacement help?
   Yes, if IgG is low or infections are frequent. It reduces infections. Medscape

9. Is stem cell transplant a cure?
   HSCT can be curative in severe, refractory disease but carries risks; only done in expert centers. JA Connections

10. Are live vaccines safe?
    Often avoided if immune function is low; your immunologist decides. Household members should use inactivated options when possible. Immune Deficiency Foundation

11. Why check bones and eyes?
    Steroids thin bones; some drugs (e.g., hydroxychloroquine) need eye checks. Medscape

12. What about cancer risk?
    Immune dysregulation may increase lymphoma risk; report fast-growing nodes or night sweats promptly. PMC

13. Can stress make symptoms worse?
    Stress can amplify symptoms and fatigue; coping tools help quality of life. Immune Deficiency Foundation

14. What if platelets get very low?
    Call your team; treatments include steroids, IVIG, rituximab, and TPO-agonists. Avoid trauma/NSAIDs. Medscape

15. Where can I learn more?
    Reputable overviews are available from hematology/immunology reviews and patient-advocacy groups. PMC+2PMC+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.